Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nutrition and physical activity professional education in gastrointestinal oncology: a national multidisciplinary survey.
Hilmi M, Pellat A, Benoit O, Foucaut AM, Mino JC, Kauffmann A, Rochet F, Heuze E, Pudlarz T, Naoun N, Garcia-Larnicol ML, Delpeut C, Peschaud F, Neuzillet C. Hilmi M, et al. Among authors: garcia larnicol ml. BMJ Support Palliat Care. 2020 Sep;10(3):324-330. doi: 10.1136/bmjspcare-2020-002342. Epub 2020 Jul 14. BMJ Support Palliat Care. 2020. PMID: 32665258
Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey.
Ouali K, Turpin A, Neuzillet C, Rousseau B, Garcia-Larnicol ML, Tournigand C, Samalin E, Taieb J, André T, Cohen R. Ouali K, et al. Among authors: garcia larnicol ml. Clin Colorectal Cancer. 2021 Mar;20(1):79-83.e4. doi: 10.1016/j.clcc.2020.11.004. Epub 2020 Nov 14. Clin Colorectal Cancer. 2021. PMID: 33281064 Free article.
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
Boilève A, Hilmi M, Gougis P, Cohen R, Rousseau B, Blanc JF, Ben Abdelghani M, Castanié H, Dahan L, Tougeron D, Metges JP, Tournigand C, Garcia-Larnicol ML, Vernerey D, Turpin A, Neuzillet C. Boilève A, et al. Among authors: garcia larnicol ml. Eur J Cancer. 2021 Jan;143:55-63. doi: 10.1016/j.ejca.2020.10.027. Epub 2020 Dec 3. Eur J Cancer. 2021. PMID: 33279854 Clinical Trial.
[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R, Pudlarz T, Garcia-Larnicol ML, Vernerey D, Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T, Louvet C, Tournigand C, Chibaudel B, Tougeron D, Guimbaud R, Benouna J, Adenis A, Sokol H, Borg C, Duval A, Svrcek M, André T. Cohen R, et al. Among authors: garcia larnicol ml. Bull Cancer. 2020 Apr;107(4):438-446. doi: 10.1016/j.bulcan.2019.11.016. Epub 2020 Feb 10. Bull Cancer. 2020. PMID: 32057467 Free article. French.
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio T, Desrame J, Lièvre A, Garcia-Larnicol ML, Pudlarz T, Cohen R, Memmi S, Vernerey D, Henriques J, Lefevre JH, Svrcek M. André T, et al. Among authors: garcia larnicol ml. J Clin Oncol. 2023 Jan 10;41(2):255-265. doi: 10.1200/JCO.22.00686. Epub 2022 Aug 15. J Clin Oncol. 2023. PMID: 35969830 Free PMC article. Clinical Trial.
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol ML, Svrcek M, Vernerey D, Menu Y, André T. Cohen R, et al. Among authors: garcia larnicol ml. J Immunother Cancer. 2020 Nov;8(2):e001499. doi: 10.1136/jitc-2020-001499. J Immunother Cancer. 2020. PMID: 33148693 Free PMC article. Clinical Trial.
Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
Hamidou Z, Chibaudel B, Hebbar M, Hug de Larauze M, André T, Louvet C, Brusquant D, Garcia-Larnicol ML, de Gramont A, Bonnetain F. Hamidou Z, et al. Among authors: garcia larnicol ml. PLoS One. 2016 Jun 16;11(6):e0157067. doi: 10.1371/journal.pone.0157067. eCollection 2016. PLoS One. 2016. PMID: 27310205 Free PMC article. Clinical Trial.
RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study.
Lucidarme O, Wagner M, Gillard P, Kim S, Bachet JB, Rousseau B, Mazard T, Louvet C, Chibaudel B, Cohen R, Garcia-Larnicol ML, Gobert A, Henriques J, André T. Lucidarme O, et al. Among authors: garcia larnicol ml. Cancer Imaging. 2019 Dec 9;19(1):85. doi: 10.1186/s40644-019-0271-z. Cancer Imaging. 2019. PMID: 31818317 Free PMC article.
Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study.
Diouf M, Chibaudel B, Filleron T, Tournigand C, Hug de Larauze M, Garcia-Larnicol ML, Dumont S, Louvet C, Perez-Staub N, Hadengue A, de Gramont A, Bonnetain F. Diouf M, et al. Health Qual Life Outcomes. 2014 May 13;12:69. doi: 10.1186/1477-7525-12-69. Health Qual Life Outcomes. 2014. PMID: 24886671 Free PMC article. Clinical Trial.
12 results